SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential to disrupt the cloud computing industry and integrate AI, with some drawing comparisons to ZCash's previous run. Bullish sentiment is fueled by recent news around the Caffeine AI platform and increased developer activity, as well as speculation about potential partnerships and exchange listings. Community members highlight ICP's unique technology and its potential to offer a decentralized alternative to traditional cloud providers like AWS and Azure.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as community members discuss its potential within the decentralized storage sector and its competition with Amazon AWS. Speculation around AI and data infrastructure projects utilizing Filecoin's network is fueling interest, with some eyeing a return to all-time highs. Technical analysis and discussions of potential breakouts are also prominent.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending as community members discuss its potential within the expanding Jasmy ecosystem, particularly around the JANCTION project and its JCT token, while also debating price action and future prospects. The discussions include speculation on potential partnerships and the impact of broader market trends. Some community members are highlighting the coin's fundamentals, while others express frustration with price movement.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending amid speculation of a potential buyout, fueled by bidding wars for competitors in the obesity drug space and renewed discussions around pipeline value. Community talking points revolve around the potential price tag Viking could command and speculation around potential acquirers like BMY. Some traders express frustration with the stock's price action, while others remain optimistic about its long-term prospects.

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Metsera Inc

MTSR is trending due to ongoing speculation around a potential buyout offer from pharmaceutical giants like $PFE and $NVO, driving community discussion about competing bids and the future of its obesity drug pipeline. The community is actively debating the potential value of MTSR's assets, with some believing the bidding war is far from over, while others suggest that potential regulatory hurdles or superior alternatives may shift focus elsewhere. Broader sector trends in weight-loss and metabolic disease treatments add further context.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings ($ONDS) is trending due to its acquisition of Sentrycs, a counter-drone technology firm, sparking discussions about its potential in the defense sector. The community is focused on how this acquisition will impact Ondas' future contracts and revenue, especially given the increasing need for counter-UAS solutions globally. Bullish sentiment is fueled by the anticipation of strong earnings and the company's strategic positioning in the growing drone and counter-drone market.

Ethereum Classic

Ethereum Classic is trending as traders discuss its potential for a significant price increase, drawing comparisons to past bull runs and anticipating a move to catch up with Ethereum's recent gains. Community members are debating entry points and potential price targets, with some highlighting its proof-of-work mechanism and perceived undervaluation as bullish factors. The conversation also includes speculation about broader altcoin season dynamics and the potential impact of upcoming economic events.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as investors discuss its potential as a meme stock with a possible short squeeze, highlighting its low float and upcoming pension transfer. The community is also focused on Kodak's diversification into batteries and pharmaceuticals, and some are anticipating news or partnerships that could drive the stock higher. Despite mixed sentiment, many are optimistic about the company's long-term growth potential.

Toyota Motor Corp. engages in the manufacture and sale of motor vehicles and parts. It operates through the following segments: Automotive, Financial Services, and All Other. The Automotive segment designs, manufactures, assembles and sells passenger cars, minivans, trucks, and related vehicle parts and accessories. It is also involved in the development of intelligent transport systems. The Financial Services segment offers purchase or lease financing to Toyota vehicle dealers and customers. It also provides retail leasing through lease contracts purchased by dealers. The All Others segment deals with the design, manufacture, and sale of housing, telecommunications and other businesses. The company was founded by Kiichiro Toyoda on August 28, 1937 and is headquartered in Toyota, Japan.

Toyota Motor Corporation - ADR

Toyota Motor Corp.

Toyota is trending as community members discuss the company's advancements in solid-state battery technology and its potential impact on the EV sector, in addition to a potential buy-out of Toyota Industries. Some are analyzing recent earnings and the company's strategic direction, with discussion about tariffs and sales growth, along with Toyota's collaboration with Waymo, as factors influencing the stock.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to an ongoing bidding war with Novo Nordisk ($NVO) to acquire Metsera ($MTSR), an obesity drug developer. The community is discussing the implications of Pfizer potentially overpaying for Metsera and whether antitrust concerns will play a role, as well as potential alternative acquisitions like Viking Therapeutics ($VKTX). Some investors are also expressing concerns about Pfizer's overall acquisition strategy and its impact on shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insights Ahead: Agenus's Quarterly Earnings

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +9.80% and -12.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates

Innoviva (INVA) delivered earnings and revenue surprises of +134.78% and +14.78%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -1,400.00% and +13.26%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanced CTLA-4 antibody and balstilimab (BAL), a PD-1...

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology, will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at 4:00 p.m. ET. The webcast will feature updates from leading...

Are Options Traders Betting on a Big Move in Agenus tock?

Investors need to pay close attention to AGEN stock based on the movements in the options market lately.

Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -28.21% and +2.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

AGEN
Agenus Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AGEN News

AGENAgenus Inc